PT  - JOURNAL ARTICLE
AU  - Amy K Keir
AU  - Emily Shepherd
AU  - Sarah McIntyre
AU  - Alice Rumbold
AU  - Charlotte Groves
AU  - Caroline Crowther
AU  - Emily Joy Callander
TI  - Antenatal magnesium sulfate to prevent cerebral palsy
AID  - 10.1136/archdischild-2021-321817
DP  - 2021 Jul 07
TA  - Archives of Disease in Childhood - Fetal and Neonatal Edition
PG  - fetalneonatal-2021-321817
4099  - http://fn.bmj.com/content/early/2021/07/06/archdischild-2021-321817.short
4100  - http://fn.bmj.com/content/early/2021/07/06/archdischild-2021-321817.full
AB  - Magnesium sulfate given to women before birth at <30 weeks’ gestation reduces the risk of cerebral palsy in their children. Our study aimed to assess the impact of a local quality improvement programme, primarily using plan-do-study-act cycles, to increase the use of antenatal magnesium sulfate. After implementing our quality improvement programme, an average of 86% of babies delivered at <30 weeks’ gestation were exposed to antenatal magnesium sulfate compared with a historical baseline rate of 63%. Our study strengthens the case for embedding quality improvement programmes in maternal perinatal care to reduce the impact of cerebral palsy on families and society.Data (de-identified only) are available upon reasonable request.